Tina Bagratuni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1770502/publications.pdf

Version: 2024-02-01

29 papers	703 citations	759233 12 h-index	580821 25 g-index
29 all docs	29 docs citations	29 times ranked	1284 citing authors

#	Article	IF	Citations
1	Kinetics of <scp>antiâ€SARSâ€CoV</scp>â€2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	4.1	5
2	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	5.2	10
3	Third dose of the <scp>BNT162b2</scp> vaccine results in very high levels of neutralizing antibodies against <scp>SARSâ€CoV</scp>â€2: Results of a prospective study in 150 health professionals in Greece. American Journal of Hematology, 2022, 97, .	4.1	10
4	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recoveryâ€"The Prospective Observational ROADMAP-Post COVID-19 Study. Hemato, 2022, 3, 111-121.	0.6	4
5	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Frontiers in Endocrinology, 2022, 13, 840668.	3.5	15
6	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	4.1	14
7	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	2.4	2
8	Comparison of neutralizing antibody responses against <scp>SARSâ€CoV</scp>â€2 in healthy volunteers who received the <scp>BNT162b2 mRNA</scp> or the <scp>AZD1222</scp> vaccine: Should the second <scp>AZD1222</scp> vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	4.1	17
9	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	2.7	7
10	Systemic IL-15, IFN-Î³, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Reports, 2021, 36, 109504.	6.4	137
11	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	5.5	52
12	The Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	1.4	0
13	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	4.1	13
14	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12, 2864.	3.7	12
15	Antiâ€"SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms, 2020, 8, 1885.	3.6	39
16	Cellâ€free <scp>DNA</scp> analysis for the detection of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations in <scp>IgM</scp> monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	4.1	12
17	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances, 2020, 4, 830-844.	5.2	54
18	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Medical Genetics, 2019, 20, 23.	2.1	8

#	Article	IF	Citations
19	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	7.2	40
20	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2018, 8, 42.	6.2	29
21	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leukemia and Lymphoma, 2017, 58, 2304-2309.	1.3	17
22	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Scientific Reports, 2017, 7, 17802.	3.3	17
23	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. Journal of Medicinal Chemistry, 2016, 59, 8787-8803.	6.4	41
24	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Blood, 2015, 126, 4188-4188.	1.4	1
25	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	1.4	0
26	Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	1.4	0
27	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomideâ€based regimens. American Journal of Hematology, 2013, 88, 765-770.	4.1	40
28	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	1.4	0
29	XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 2010, 116, 250-253.	1.4	107